Clozapine is a potent atypical antipsychotic which binds to a variety of neurotransmitter receptors including serotonin (5-HT) receptors. However, the precise neurochemical site of clozapine's therapeutic action is unknown. We hypothesize that genetic variation in the neurotransmitter receptors to which the drug binds may influence clozapine response. To test this hypothesis we genotyped a novel −1438-G/A polymorphism detected in the promoter region, and a His452Tyr polymorphism described in the coding region of the 5-HT 2A receptor gene in two independent samples of clozapine-treated patients including responders and nonresponders. Although the strong association between these polymorphisms and clozapine response observed in the first sample (sample I) was not statistically significant in the second sample (sample II), the results in both samples were in the same direction. Homozygosity for the allele G-1438 was higher among non-responders (56% in sample I, 43% in sample II) than in responders (28% in sample I and 32% in sample II) in both samples. Similarly, the frequency of allele Tyr452 was higher in non-responders (11% in sample I, 16% in sample II) than in responders (6% in sample I and 10% in sample II). A combined analysis of both samples showed association between both polymorphisms and clozapine response. These results provide further evidence suggesting that genetic variation at 5-HT 2A receptors may influence clozapine response and strengthen the candidacy of these receptors as important therapeutic targets.
Introduction
mediate treatment response will be an important step in understanding the mechanisms of antipsychotic Serotonin neurotransmitter receptors are now recogdrug action. nised as potentially important therapeutic targets for a Previously, we hypothesised that clinical response variety of antipsychotic drugs, particularly those to antipsychotic drugs may be determined by genetic termed atypical because of their reduced propensity to variation in the neurotransmitter receptor to which the induce extrapyramidal side-effects. 1 Clozapine, for drug binds. In this way, alterations in genes coding for example, is characterised by fewer extrapyramidal receptor proteins may affect their binding affinities for symptoms, high affinity for 5-HT 2A and 5-HT 2C recepneuroleptics, the efficiency of signal transduction or tors and relatively low occupancy of dopamine D 2 their levels of expression which may in turn alter the receptors in comparison to classical antipsychotics drug's therapeutic action. In support of this hypothesis, such as haloperidol. 2 In addition, clozapine is effective we found association between a silent 102-T/C polyin the treatment of up to 50% of patients who have morphism in the 5-HT 2A receptor gene and clinical failed to respond to other antipsychotic drugs.
3 Howresponse in a group of schizophrenic patients treated ever, the precise neurochemical site of clozapine's with clozapine. 4 Several groups have attempted to reptherapeutic action is unknown since it binds to a wide licate this association with varying success.
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variety of neurotransmitter receptors including seroThe 102-T/C polymorphism has also been reported tonergic, dopaminergic, histaminergic, muscarinic and to be associated with schizophrenia in a series of indeadrenergic receptors. Identifying those receptors which pendent studies. In addition to the 102-T/C polymorphism, we also annealing temperature of 58°C were performed in a PCR mix containing 50 ng of template DNA, 2.5 mM of found association between a structural polymorphism in the 5-HT 2A gene, a His452Tyr substitution, and poor MgCl 2 and 1 l of each of the following primers: 5′-AAGCTGCAAGGTAGCAACAGC-3′ and 5′-AACresponse to clozapine, 18 a finding which has been replicated in an independent sample of clozapine-treated CAACTTATTTCCTACCAC-3′. The 468-bp product was digested with MspI and the alleles separated in a patients. 19 Since the 102-T/C polymorphism does not cause a 2% agarose gel. Allele 2 (G at −1437) was digested in two fragments of 244 and 224 bp. change in the amino acid sequence of the 5-HT 2A receptor, it may reflect the effect on clozapine response The methods and primers described by Erdmann and collaborators 11 were used for the amplification of a 248-of a functional polymorphism elsewhere in the gene through linkage disequilibrium. Recently a novel G to bp fragment including the His452Tyr polymorphism. Briefly, PCR amplification was performed using 100 ng A base change at position −1438 of the 5-HT 2A promoter region has been detected which is in very strong of template DNA, 2.0 mM of MgCl 2 , 200 mM dNTPs, 1 M of each primer and 1 U of Tap polymerase. After linkage disequilibrium with the 102-T/C polymorphism (Spurlock et al, submitted). We hypothesized 35 cycles of 1′ at 95°C, 45′′ at 58°C, and 45′′ at 72°C, the PCR products were digested with 10 U of BbvI at that both this genetic variant and the structural His452-Tyr may be directly involved in determining clinical 37°C overnight. Allele His452 was digested in two fragments of 180 bp and 68 bp, whereas allele Tyr452 was response to clozapine and in the aetiology of schizophrenia. To test this hypothesis, a sample of 160 clozauncut. The digested fragments were analysed in 3% agarose gels next to a DNA size standard. pine-treated patients (sample I), including 102 responders and 58 non-responders, and a sample of 178 controls were genotyped for the G-1438A polymorResults phism. In addition, a newly ascertained sample of 114 clozapine-treated patients (sample II) including 79
The results of analyses of the −1438-G/A polymorphism and clinical response to clozapine are shown in responders and 35 non-responders was analysed as an independent replication sample. This sample was Tables 1 and 2 . A strong association between the −1438-G/A polymorphism and clinical response to clogenotyped for both 5-HT 2A polymorphisms, −1438-G/A and His452Tyr.
zapine was found in sample I. This is not surprising since this polymorphism is in almost complete linkage disequilibrium with 102-T/C which previously showed Material and methods positive results in the same sample. 4 In this sample, homozygosity for the G-1438 allele was more frequent Description of samples Sample I consisted of 160 patients with a DSM-III-R among non-responders (56%) than in responders (28%) ( Table 1) . This difference was statistically sigdiagnosis of schizophrenia and 178 normal control subjects and has been previously described. 4 All nificant ( 2 = 12.07, P = 0.002 for genotype frequency relative to clozapine response and 2 = 11.86, patients and controls were white Caucasians of British origin. The patients had previously shown resistance P = 0.0006 if G-1438 was considered recessive, OR = 3.25). These results agree with our previous findto at least two different types of neuroleptics and had been treated with clozapine for at least 3 months. Clozing 4 showing that individuals homozygous for allele C102 (in linkage disequilibrium with G-1438) were apine doses varied between 125 mg and 600 mg daily. Clinical response was determined by the global assessmore frequent in those patients showing poor response to clozapine. Analysis of allele frequencies also ment score (GAS) scales and a 20-point improvement in the scale after clozapine treatment was considered showed a significant association between allele G-1438 and poor response to clozapine ( 2 = 8.25, P = 0.004, as cut-off for response. The sample comprised 102 patients classified as responders and 58 classified as OR = 2.05). The results of genotyping this polymorphism in a second independent sample of clozapinenon-responders.
A second independent sample (sample II) of 114 clotreated patients (sample II) did not replicate the strong associations found in sample I. However, sample II also zapine-treated patients including 79 responders and 35 non-responders was collected in various centres in the showed an excess of homozygosity for allele G-1438 among non-responders (43%) than in responders UK. This sample has not been previously described and was collected for use in replication studies of our (32%) and allele G-1438 was more frequent in nonresponders (0.63) than in responders (0.58). However, earlier findings. Identical criteria as in sample I were used for the measurement of clinical response and these differences were not statistically significant although the odds ratios were relatively high diagnosis of the patients. Collection of clinical data from both samples was carried out by the same team (OR = 1.62 for genotype frequencies considering G-1438 recessive, and OR = 1.21 for allele association). of psychiatrists (RK and JM).
No significant heterogeneity in odds ratios between samples was detected ( 2 = 1.64, P = 0.20, recessive Detection of polymorphisms The −1438-G/A polymorphism in the promoter region model) and combined analysis was performed after pooling the two samples. Combined analysis of both of the 5-HT 2A gene was detected using the following protocol: 35 cycles of PCR amplification at an samples showed strong association of genotype fre- an improvement higher than 25 GAS score points (GAS diffϾ25) and lower than 15 GAS points (GAS diffϽ15) after clozapine treatment quencies with clinical response to clozapine sensitivity of our method, further statistical analyses including only those patients who showed a change ( 2 = 12.40, P = 0.0006, OR = 2.46). Allele frequencies also showed association with clozapine response in the higher than 25 GAS points (GAS diffϾ25) or lower than 15 GAS points (GAS diffϽ15) were performed. The cutcombined analysis ( 2 = 6.99, P = 0.008, OR = 1.65). Sample II was also genotyped for the 102-T/C polymoroff point was chosen in order to minimize the error without excessive loss of statistical power. Narrower phism but since only three patients showed recombinant genotypes between 102-T/C and −1438-G/A the selection of extreme responders would increase the differences in genotype and allele frequencies but would results were very similar and the data are not shown.
Sample I Sample II Combined analysis Responders Non-responders Responders Non-responders Responders Non-responders (GAS diffϾ25) (GAS diffϽ15) (GAS diffϾ25) (GAS diffϽ15) (GAS diffϾ25) (GAS diffϽ15)
A significant number of patients (59 in sample I and dramatically decrease the sample size. This method of selecting phenotypic extremes is commonly used for 52 in sample II) showed moderate response with improvement of between 15 and 25 GAS points after the analysis of quantitative traits. 20, 21 The results are shown in Table 2 . After exclusion of the intermediate clozapine treatment. Considering that the assessment of clinical response is partly subjective and not precise, responders, genotype and allele frequencies were very similar in both samples. Genotype frequencies were some misclassification of patients' response is expected, especially in the patients close to the 20- significantly different between responders and nonresponders in the three groups, particularly when conpoint cut-off for improvement. In order to increase the sidering G-1438 recessive (P = 0.02, OR = 2.64 for samzapine-treated patients and controls (data not shown). Further analysis of data excluding patients with modple I, P = 0.03, OR = 3.22 for sample II and P = 0.001, OR = 2.90 for combined analysis). Allelewise analysis erate clozapine response was not possible due to the small number of patients with a Tyr452 allele. was not significant for the separate samples although the odds ratios were relatively high (1.61 for sample I, 1.75 for sample II and 1.69 for the combined sample). Allele G-1438 was more frequent among nonDiscussion responders and this reached statistical significance in the combined analysis ( 2 = 4.82, P = 0.03, OR = 1.69).
In a previous study 4 we reported a strong association between a silent 5-HT 2A 102-T/C polymorphism and No differences in genotype or allele frequencies were observed when comparing the samples of clozapineclinical response to clozapine. In addition, a structural His452Tyr change was also associated with clinical treated patients with a group of controls (data not shown).
response to clozapine. 18 This finding was supported by the results of Badri and collaborators 19 who indepen- Table 3 summarises the results of genotyping the His452Tyr polymorphism (data from sample I were dently found association between this His452Tyr polymorphism and clozapine response. These results included in a previous study 18 ). Similar results were obtained in sample I and sample II. Allele Tyr452 was strengthened the hypothesis that genetic variation in 5-HT 2A receptors affects clinical response to clozapine. rare and only four subjects were homozygous for this allele in sample I and one in sample II. The frequency However, the strong association we found between the 102-T/C polymorphism and clozapine response was of patients with at least one Tyr452 allele was always higher among non-responders than in responders, not replicated by other groups 5-8 although they also found an increased frequency of patients homozygous although the differences did not reach statistical significance. Comparison of the combined genotype frefor the C102 allele among non-responders. To clarify these results, an independent sample of quencies in responders and non-responders from both samples showed a trend towards association with clozclozapine-treated patients was collected (sample II). This sample was genotyped for the polymorphisms apine response which reached statistical significance when considering Tyr452 recessive ( 2 = 4.82, found to be associated with poor clinical response in sample I, 102-T/C and His452Tyr. In addition, this P = 0.03). The frequency of the Tyr452 allele was also found to be higher among non-responders in both sample, and sample I, were genotyped for a −1438-G/A polymorphism detected in the promoter region of 5-samples. Borderline significance was observed when comparing allele frequencies in responders and non-HT 2A . This polymorphism was found to be in almost complete linkage disequilibrium with the silent 102-responders from both samples ( 2 = 3.37, P = 0.06). However, the calculated odds ratios, which are not so T/C polymorphism. Since the 102-T/C change does not cause an amino acid substitution in the receptor promuch affected by sample size as chi-square analysis, were particularly high for genotype (OR = 5.51 for samtein, it is unlikely to affect receptor function or expression which may be directly related to clinical ple I and 8.09 for the combined analysis) and allele frequencies (1.85 for sample I, 1.65 for sample II and response to clozapine. It is more likely that the −1438-G/A polymorphism, and not 102-T/C, has an effect on 1.70 for the combined analysis). No differences were observed in genotype or allele frequencies between cloreceptor expression and influences clozapine response, although this hypothesis must be confirmed with funca minor role in the aetiology of schizophrenia 12 which may be detected in studies of large samples such as tional studies.
As expected, we found that the −1438-G/A was also those reported by Williams and collaborators. 9 In summary, associations were found between two strongly associated with clinical response to clozapine in the original sample (sample I). This strong associ-5-HT 2A polymorphisms, −1438-G/A and His452Tyr and clozapine response in a combined sample of clozapineation was not replicated in sample II, although genotype and allele frequencies of G-1438 were also greater treated patients. The real strength of this association needs to be confirmed with appropriated meta-analyin non-responders. Combined analysis of both samples showed strong association with clozapine response sis. However, these results provide further evidence of the influence of genetic variation in 5-HT2A receptors which may be primarily due to the contribution of sample I. However, some error in the assessment of the in clozapine and strengthen the candidacy of 5-HT 2A receptors as important therapeutic targets in schizopatients' response should be assumed. To minimize the effect of this error in the statistical analysis, further calphrenia. A repetition of these studies on samples of patients treated with other serotonin targeting antipsyculations were performed excluding those patients who showed moderate improvement in response and chotics such as risperidone, olanzapine and sertindole would help to confirm and clarify the importance of are more likely to have been misclassified. An argument in favour of such selection is provided by the the 5-HT 2A receptors as therapeutic targets. similarity of genotype and allele frequencies observed in both samples after exclusion of the intermediate
